Date:2/21/2013

and technical issues; market conditions and  other risks inherent to medical and/or telecom device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our prospectus supplement on Form 424b2,  and other filings made with the Securities and Exchange Commission. Additional information will also be set forth in our Form 10-K that will be filed for the year ended December 31, 2012, which should be read in conjunction with these financial results. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.VOLCANO CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP EPS GUIDANCE(in thousands, except per share data)(Unaudited)2013Guidance RangeFromTo GAAP net loss per share—basic 

$  (0.23)$  (0.19) GAAP net loss per share—diluted 

$  (0.22)$  (0.19)  Acquisition related items 

0.050.05  Amortization of intangibles 

0.040.04  Non-cash interest expense 

0.210.21 Non-GAAP net income per share—diluted 

$
.08$
.11 Weighted average shares outstanding—basic 

54,40054,400 Weighted average shares outstanding—diluted 

56,20056,200Note: Effective tax rate of 38% applied to non-GAAP adjustments
'/>"/>

SOURCE Volcano Corporation Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Volcano Announces Record Fourth Quarter Revenues
2. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
3. Volcano Corporation Prices Offering Of $400 Million 1.75% Convertible Senior Notes Due 2017
4. Volcano Corporation To Offer $350 Million Convertible Senior Notes Due 2017
5. Volcano Corporation Signs Agreement to Acquire Sync-Rx Ltd.
6. Volcano Corporation Presentation At Piper Jaffray Conference To Be Webcast
7. Fish & Richardson Prevails in Patent Infringement Trial for Volcano Corporation
8. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
9. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
10. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
11. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial